Form 4: Carisma Therapeutics Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Michael Klichinsky, Chief Scientific Officer of Carisma Therapeutics Inc., reports the acquisition of stock options.
Summary
- Michael Klichinsky, the Chief Scientific Officer of Carisma Therapeutics Inc., filed a Form 4.
- The filing reports the acquisition of 221,000 stock options on January 28, 2025, at an exercise price of $0.50.
- The options vest over four years in equal monthly installments, contingent upon continued service to Carisma Therapeutics Inc., and expire on January 28, 2035.
- Following the transaction, Klichinsky directly owns 221,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of key personnel.
Stakeholder Impact
- The acquisition of stock options by a key executive aligns their interests with those of the shareholders, potentially incentivizing them to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of earliest transaction and acquisition of stock options. |
| 01/30/2025 | Date of signature for the Form 4 filing. |
| 01/28/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.